Latest News and Press Releases

Swissmedic grants marketing authorization for PYLCLARI® in Switzerland b.e. Imaging is marketing authorization holder and has exclusive distribution rights for PYLCLARI® across Switzerland ZURICH,...

The acquisition of Nucleis will: Enhance Curium’s PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western EuropeImprove reliability and accessibility...

ST. LOUIS, April 02, 2025 (GLOBE NEWSWIRE) -- Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation of Technetium Tc 99m...

วางตำแหน่ง Curium เป็นผู้ผลิตไอโซโทป Lu-177 ชั้นนำนำความเชี่ยวชาญด้านการวิจัยและพัฒนาที่เป็นนวัตกรรมและลำดับขั้นตอนการทำงานมาสู่ Curiumเพิ่มความครอบคลุมทางภูมิศาสตร์และห่วงโซ่อุปทาน SPECT & PET...

Posiciona a Curium como fabricante líder de isótopo Lu-177Aporta experiencia innovadora en I+D y una línea de desarrollo de productos a CuriumMejora la cobertura geográfica y la cadena de suministro...

Aquisição posiciona a Curium como principal fabricante do isótopo Lu-177Oferece experiência inovadora em P&D e pipeline para a CuriumAprimora a cobertura geográfica e a cadeia de suprimentos SPECT...

Curium, 루테튬-177 동위원소 선도적 제조업체로 자리매김Curium은 혁신적인 R&D 전문성과 파이프라인 확보 효과Curium의 SPECT 및 PET 지리적 범위와 공급망 강화 파리, March 29, 2025 (GLOBE NEWSWIRE) -- 핵의학 분야를 선도하는 Curium Pharma(이하 “Curium”)가 터키 이스탄불에...

Menempatkan Curium sebagai produsen terkemuka isotop Lu-177Memberikan keahlian Litbang dan rangkaian tahap pengembangan produk (pipeline) yang inovatif ke CuriumMeningkatkan jangkauan geografis dan...

Dies positioniert Curium als führenden Hersteller des Isotops Lu-177Integration innovativer F&E-Expertise und Pipeline für CuriumVerbesserung der geografischen Abdeckung und Lieferkette von Curium...

确立了 Curium 的镥-177 同位素领先制造商地位为 Curium 注入创新的研发专业技术和产品管线拓展 Curium 的 SPECT 和 PET 地理覆盖范围和供应链 巴黎, March 29, 2025 (GLOBE NEWSWIRE) -- 全球核医学领域领导者 Curium Pharma (“Curium”) 宣布完成对 Eczacıbaşı-Monrol Nuclear...